Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
161.3 USD | +0.33% | -0.89% | +4.07% |
May. 13 | AbbVie, Gilgamesh Pharmaceuticals Partner to Develop Therapies for Psychiatric Disorders | MT |
May. 09 | Medincell: share price rises on resumption of trading | CF |
Financials (USD)
Sales 2024 * | 54.95B | Sales 2025 * | 57.98B | Capitalization | 285B |
---|---|---|---|---|---|
Net income 2024 * | 7.74B | Net income 2025 * | 10.65B | EV / Sales 2024 * | 6.16 x |
Net Debt 2024 * | 53.62B | Net Debt 2025 * | 47.29B | EV / Sales 2025 * | 5.73 x |
P/E ratio 2024 * |
31.3
x | P/E ratio 2025 * |
24
x | Employees | 50,000 |
Yield 2024 * |
3.83% | Yield 2025 * |
4.03% | Free-Float | 96.37% |
Latest transcript on AbbVie Inc.
1 day | +0.33% | ||
1 week | -0.89% | ||
Current month | -0.84% | ||
1 month | -0.62% | ||
3 months | -6.93% | ||
6 months | +16.33% | ||
Current year | +4.07% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Gonzalez
CEO | Chief Executive Officer | 70 | 12-12-31 |
Scott Reents
DFI | Director of Finance/CFO | 57 | 12-12-31 |
Robert Michael
PSD | President | 53 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 63 | 12-12-31 |
Edward Rapp
BRD | Director/Board Member | 66 | 12-12-31 |
Director/Board Member | 70 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
7.12% | 6 M€ | +7.34% | - | |
6.85% | 17 M€ | +6.46% | - | |
6.26% | 13 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 161.3 | +0.33% | 3,505,882 |
24-05-10 | 160.8 | +0.22% | 3,509,603 |
24-05-09 | 160.4 | -0.03% | 3,570,072 |
24-05-08 | 160.4 | -1.29% | 5,906,701 |
24-05-07 | 162.6 | -0.11% | 5,301,668 |
Delayed Quote Nyse, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.07% | 285B | |
+29.98% | 682B | |
+30.34% | 586B | |
-3.52% | 364B | |
+18.59% | 327B | |
+16.21% | 240B | |
+9.66% | 209B | |
-6.83% | 203B | |
+7.09% | 165B | |
-1.22% | 161B |
- Stock Market
- Equities
- ABBV Stock